revenue

SAN DIEGO--(BUSINESS WIRE)--New Harvard Business Review Analytic Services research sponsored by Seismic reveals execution gap and highlights AI as a critical lever for growth.

(NASDAQ:CRWD) AUSTIN, Texas--(BUSINESS WIRE)--Fal.Con 2025, Las Vegas -- CrowdStrike (NASDAQ: CRWD) today announced results from an independent study by Canalys, now part of Omdia, showing that partners can generate up to $7 in services revenue for every $1 customers spend on the CrowdStrike Falcon® platform. This return represents the strongest cybersecurity partner ecosystem multiplier on record, illustrating the generational ecosystem significance of the Falcon platform. The study examined CrowdStrike glo

SAN FRANCISCO--(BUSINESS WIRE)--Front, the AI-powered customer operations platform, today announced it has surpassed $100 million in annual recurring revenue (ARR). The achievement is a rare milestone reached by less than 1% of SaaS businesses and reflects the company’s continued focus on building technology that combines human connection with operational excellence. Founded on the belief that strong customer relationships are the foundation of every great business, Front helps over 9,000 compa

(NASDAQ:KSCP) SUNNYVALE, Calif.--(BUSINESS WIRE)--Knightscope, Inc. (NASDAQ: KSCP), a leader in autonomous security robots and emergency communication devices, today announced that it has signed another $1 million in contract renewals, expansions and newly won sales. This momentum highlights the increasing priority organizations are placing on modern, technology-driven approaches to building safer and more secure environments. Nationwide Emergency Communication Device (ECD) Expansion Knightscope has secured

With global demand for localized content at an all-time high, Deepdub's AI-powered voice solutions are unlocking new income streams for creative professionals across the media and entertainment industry TEL AVIV, Israel, Aug. 21, 2025 /PRNewswire/ -- Deepdub, the foundational voice AI...

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

LAGUNA HILLS, Calif., Aug. 7, 2025 /PRNewswire/ -- It's no secret that pigment is one of the most fickle conditions to treat. With an unpredictable nature influenced by a variety of factors, such as genetics, skin type, hormonal changes, and more, achieving consistent results can seem...